These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15136407)

  • 1. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
    Cunha BA
    Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
    Roig J; Casal J; Gispert P; Gea E
    Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
    Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
    Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ; Arnold C; Bassetti S
    Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
    Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
    Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate outpatient macrolide use in community-acquired pneumonia.
    Gotfried MH
    J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
    Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
    BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
    Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
    Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
    Garin N; Nendaz M
    Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
    Epstein BJ; Gums JG
    Drugs; 2005; 65(14):1949-71. PubMed ID: 16162020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
    van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
    Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia.
    Read RC
    J Infect; 1999 Nov; 39(3):171-8. PubMed ID: 10714789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
    BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
    Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
    JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.